[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4449 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 4449

       To establish the Commission on Strengthening the Domestic 
          Pharmaceutical Supply Chain, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             June 30, 2023

    Mr. Torres of New York introduced the following bill; which was 
            referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
       To establish the Commission on Strengthening the Domestic 
          Pharmaceutical Supply Chain, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Pharmaceutical Security Production 
Act''.

SEC. 2. COMMISSION ON STRENGTHENING THE DOMESTIC PHARMACEUTICAL SUPPLY 
              CHAIN.

    (a) Establishment.--There is established a commission to be known 
as the ``Commission on Strengthening the Domestic Pharmaceutical Supply 
Chain'' (in this section referred to as the ``Commission'') to assess 
the current security and vulnerabilities of the United States 
pharmaceutical supply chain.
    (b) Duties.--The duties of the Commission are the following:
            (1) Determine concrete timelines and metrics for success 
        for the Pharmaceutical Manufacturing in America program of the 
        Biomedical Advanced Research and Development Authority to 
        produce advanced pharmaceutical ingredients for medicines 
        included in the essential medicines list.
            (2) Evaluate and identify vulnerabilities in the existing 
        United States pharmaceutical supply chain that could be 
        exploited by foreign adversaries and nonstate actors.
            (3) Review and propose solutions to strengthen the domestic 
        pharmaceutical manufacturing workforce to support increased 
        production of advanced pharmaceutical ingredients and finished 
        drugs.
            (4) Assess how Federal health care programs (as defined in 
        section 1128B(f) of the Social Security Act (42 U.S.C. 1320a-
        7b(f))), the program established under chapter 89 of title 5, 
        United States Code, and provider facilities can be used to 
        create a viable financial market for domestically made advanced 
        pharmaceutical ingredients and finished drug products.
            (5) Review the successes and failures of Operation Warp 
        Speed and determine if any best practices for public-private 
        partnerships can be used to bolster domestic manufacturing of 
        advanced pharmaceutical ingredients and finished drug products.
            (6) Estimate the Federal funding necessary to catalyze and 
        strengthen domestic pharmaceutical manufacturing.
            (7) Identify facilities throughout the United States that 
        can be repurposed to produce advanced pharmaceutical 
        ingredients, especially advanced pharmaceutical ingredients 
        listed on the essential medicines list.
            (8) Identify partner countries where advanced 
        pharmaceutical ingredients and finished drug products could be 
        manufactured to reduce dependence on China and other countries.
            (9) Provide recommendations on legislative and regulatory 
        actions that can be taken to address vulnerabilities in the 
        United States pharmaceutical supply chain and increase the 
        number of manufacturers of advanced pharmaceutical ingredients 
        and finished drug products in the United States.
            (10) Identify and propose steps that can be taken to 
        increase coordination among different Federal and State 
        programs to increase manufacturing of domestic advanced 
        pharmaceutical ingredients and finished drug products.
    (c) Membership.--
            (1) In general.--The Commission shall be composed of at 
        least 6 but not more than 11 members as follows:
                    (A) The National Security Advisor, who shall serve 
                as co-chair.
                    (B) The White House Domestic Policy Council, who 
                shall serve as co-chair.
                    (C) The Secretary of Health and Human Services.
                    (D) The Secretary of Defense.
                    (E) The Secretary of State.
                    (F) The Secretary of Commerce.
                    (G) Not more than 5 members as may be appointed by 
                joint action of the co-chairs of the Commission, from 
                among the employees and officers of appropriate Federal 
                departments and agencies.
            (2) Terms.--Each member shall be appointed for the life of 
        the Commission.
            (3) Quorum.--A majority of the Commission shall constitute 
        a quorum but a lesser number may hold hearings.
    (d) Powers of Commission.--The Commission may, for the purpose of 
carrying out this Act, hold hearings, sit and act at times and places, 
take testimony, and receive evidence as the Commission considers 
appropriate.
    (e) Reports.--
            (1) In general.--Not later than 1 year after the date of 
        enactment of this Act, and annually thereafter until the date 
        of the termination of the Commission under subsection (f), the 
        Commission shall submit to Congress a report detailing the 
        findings, conclusions, and recommendations of the Commission in 
        fulfilling its duties under subsection (b).
            (2) Form of reports.--The reports described in paragraph 
        (1) shall be submitted in unclassified form but may include a 
        classified annex.
    (f) Termination.--The Commission shall terminate on the date that 
is 4 years after the date of enactment of this Act.
    (g) Essential Medicines List Defined.--In this section, the term 
``essential medicines list'' means the list of the Food and Drug 
Administration described in section 3(c) of Executive Order 13944.
                                 <all>